KathyDMillerMD

Oncology • Indianapolis, IN

Associate Professor of Medicine, Indiana University

Join to view full profile

Dr. Miller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Miller's full profile

Already have an account?

Office
1030 W Michigan St
Indianapolis, IN 46202
Phone+1 317-944-0920
Is this information wrong?

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1997
Johns Hopkins UniversityResidency, Internal Medicine, 1991 - 1994
Johns Hopkins University School of MedicineClass of 1991

Certifications & Licensure

IN State Medical License 1994 - 2025
ND State Medical License 1997 - 1999
MN State Medical License 1997 - 1999

Awards, Honors, & Recognition

Indianapolis Monthly Castle Connolly, 2011, 2013

Clinical Trials

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2002 Jan 29
Completed
Phase 3
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer Start of enrollment: 2005 Sep 01
Terminated
A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment Start of enrollment: 2007 Apr 01
Completed
Phase 1
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer Start of enrollment: 2007 Oct 01
Terminated
Phase 2
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer Start of enrollment: 2008 Apr 01
Completed
Not Applicable
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer Start of enrollment: 2008 Jul 01
Completed
Phase 1
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer Start of enrollment: 2008 Nov 01
Completed
Not Applicable
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
Completed
Phase 2
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 1
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC Start of enrollment: 2012 Jul 01
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Start of enrollment: 2012 Nov 01
Completed
Phase 1
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer Start of enrollment: 2020 Apr 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Horm...
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara Abdou, Elizabeth C Riley, ...> ;Journal of Clinical Oncology. 2024 Mar 21
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Smith, K., Zhao, F., Mayer, I., Tevaarwerk, A., Garcia, S., Arteaga, C., Symmans, W., Park, B., Burnette, B., Makower, D., Block, M., Morley, K., Jani, C., Mescher, C....> ;Cancer. 2024 Jan 18
De Novo Oligometastatic Breast Cancer.
Lajos Pusztai, Mariya Rozenblit, Peter Dubsky, Thomas Bachelot, Anna M Kirby, Barbro K Linderholm, Julia R White, Steven J Chmura, Lisa A Carey, Boon H Chua, Kathy D M...> ;Journal of Clinical Oncology. 2023 Dec 1
ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients.
Stefania Pianetti, Kathy D Miller, Hannah H Chen, Sandra Althouse, Sha Cao, Steven J Michael, Gail E Sonenshein, Nora D Mineva> ;Cancer Cell International. 2023 Aug 11
1 citations
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, Christine Deutschmann, Stephanie Kacerovsky-Strobl, Miguel Martin, Jane Lowe Meisel, Nicholas Zdenkowski, Sibylle Loib...> ;Journal of Clinical Oncology. 2023 Nov 20
A New Look asLooks to the Future.
Kathy D Miller, Angela Cochran, Emilie Gunn, Jonathan W Friedberg> ;Journal of Clinical Oncology. 2023 Jul 1
3 citations
Use of Large Language Models and Artificial Intelligence Tools in Works Submitted to.
Kathy Miller, Emilie Gunn, Angela Cochran, Hal Burstein, Jonathan W Friedberg, Stephanie Wheeler, Paul Frankel> ;Journal of Clinical Oncology. 2023 Jul 1
3 citations
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G Abramson, Ashka Patel, Ju Cheng, Adam Brufsky, Justin Rhoade...> ;Medrxiv. 2023 Mar 8
Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women.
Roisin M Connolly, Kathy D Miller> ;Journal of Clinical Oncology. 2023 Mar 1
1 citations
ASCO Living Guidelines: The Next Frontier.
Veda N Giri, Thomas K Oliver, R Bryan Rumble, Jonathan W Friedberg, Kathy D Miller, Rachel L Geisel> ;Journal of Clinical Oncology. 2023 Feb 10
Turns 40.
Kathy D Miller, Jonathan W Friedberg> ;Journal of Clinical Oncology. 2023 Jan 1
Reply to K. Nozawa et al.
Bryan P Schneider, Tarah J Ballinger, Guanglong Jiang, Fei Shen, Nawal Kassem, Kathy D Miller> ;Journal of Clinical Oncology. 2022 Jun 10
4 citations
Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
Tarah J Ballinger, Guanglong Jiang, Fei Shen, Kathy D Miller, George W Sledge Jr, Bryan P Schneider> ;Cancer. 2022 Jun 1
Introducing Clinical Trial Updates.
Kathy D Miller, Jonathan W Friedberg> ;Journal of Clinical Oncology. 2022 May 20
4 citations
Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
Milan Radovich, Jeffrey P Solzak, Chao J Wang, Bradley A Hancock, Sunil Badve, Sandra K Althouse, Steven M Bray, Anna Maria V Storniolo, Tarah J Ballinger, Bryan P Sch...> ;Clinical Cancer Research. 2022 Aug 2
3 citations
Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Res...
Soudabeh Fazeli, Bradley S Snyder, Ilana F Gareen, Constance D Lehman, Seema A Khan, Justin Romanoff, Constantine A Gatsonis, Ralph L Corsetti, Habib Rahbar, Derrick W...> ;JAMA Network Open. 2022 May 2
2 citations
Correction to: Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
R Jagsi, G Mason, B A Overmoyer, W A Woodward, S Badve, R J Schneider, J E Lang, M Alpaugh, K P Williams, D Vaught, A Smith, K Smith, K D Miller> ;Breast Cancer Research and Treatment. 2022 Apr 1
11 citations
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
R Jagsi, G Mason, B A Overmoyer, W A Woodward, S Badve, R J Schneider, J E Lang, M Alpaugh, K P Williams, D Vaught, A Smith, K Smith, K D Miller> ;Breast Cancer Research and Treatment. 2022 Apr 1
16 citations
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Hum...
Erica L Mayer, Christian Fesl, Dominik Hlauschek, Laura Garcia-Estevez, Harold J Burstein, Nicholas Zdenkowski, Viktor Wette, Kathy D Miller, Marija Balic, Ingrid A Ma...> ;Journal of Clinical Oncology. 2022 Feb 10
10 citations
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer.
Joseph A Sparano, Anne O'Neill, Noah Graham, Donald W Northfelt, Chau T Dang, Antonio C Wolff, George W Sledge, Kathy D Miller> ;NPJ Breast Cancer. 2022 Feb 8
13 citations
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breas...
Bryan P Schneider, Guanglong Jiang, Tarah J Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C Lynce, Christopher Gallagher, Claudine Isaa...> ;Journal of Clinical Oncology. 2022 Feb 1
60 citations
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal J Burstein, Richard Greil, Peter Fox, Antonio C Wolff, Arlene Chan, Eric P Winer, Georg Pfeiler, Kath...> ;Journal of Clinical Oncology. 2022 Jan 20
3 citations
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of...
Edward H. Ip, Santiago Saldana, Kathy D. Miller, Ruth C. Carlos, Ilana F. Gareen, Joseph A. Sparano, Noah Graham, Fengmin Zhao, Ju-Whei Lee, Nathaniel O'Connell, David...> ;Cancer. 2021 Nov 2
5 citations
Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Gr...
Soudabeh Fazeli, Bradley S. Snyder, Ilana F. Gareen, Constance D. Lehman, Seema A. Khan, Justin Romanoff, Constantine Gatsonis, Kathy D. Miller, Joseph A. Sparano, Chr...> ;JAMA Network Open. 2021 Nov 1
31 citations
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade ...
Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J Haley, Anna Maria Storniolo, Mridula P ...> ;Clinical Cancer Research. 2021 Oct 29
Join now to see all

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology

Lectures

Using the Neoadjuvant Approach in Developing Novel Therapies in ER+ Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Review and Interpretation of the 2012 San Antonio Breast Cancer Symposium
Indiana University School of Medicine, Indianapolis, Indiana - 1/19/2013
2012 ACCA Northeast Regional Conference
American Academy of Medical Administrators (AAMA), Wynnewood, Pennsylvania - 10/12/2012
2012 Best of ASCO San Diego
American Society of Clinical Oncology(ASCO), San Diego, California - 8/10/2012
2012 Best of ASCO Boston
American Society of Clinical Oncology(ASCO), Boston, Massachusetts - 8/3/2012
Join now to see all

Authored Content

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Press Mentions

New Trials in Breast Cancer: Could Your Patient Benefit?May 16th, 2023
New Data for ER+ Breast Cancer: Oral SERDs, Pregnancy for Young Patients, and Emerging TargetsJanuary 3rd, 2023
Overworked Nurses; Bacteria Resistance; And New Cancer TrialsNovember 22nd, 2022
Join now to see all